Switzerland’s Obseva eyes China re-start for fertility drug that failed trial

ZURICH (Reuters) – ObsEva struck a pact with China’s Yuyuan BioScience Technology to develop and commercialize the fertility drug nolasiban, the Swiss drugmaker said on Monday as it seeks to inject new life into a medicine that had flopped a trial. In November... More »